SLC5A2 and chronic kidney disease: KDIGO similarly recommends a first-line combination glucose-lowering regimen including metformin plus a SGLT2 inhibitor in patients with T2D and CKD, unless contraindicated.67 KDIGO recommends an SGLT2 inhibitor for patients with T2D and CKD (eGFR >20 mL/min/1.73 m2), irrespective of albuminuria, based on evidence suggesting that SGLT2 inhibitors confer consistent kidney and cardiovascular benefits irrespective of albuminuria.67